TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - MEDTRONIC Stock

Certificat

DE000SD53WC0

Delayed Deutsche Boerse AG 11:39:44 2024-05-23 EDT
4.08 EUR +6.25% Intraday chart for TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - MEDTRONIC
Current month-12.33%
1 month-12.33%
Date Price Change
24-05-23 4.08 +6.25%
24-05-22 3.84 -1.03%
24-05-21 3.88 -0.77%
24-05-20 3.91 +2.89%
24-05-17 3.8 -0.78%

Delayed Quote Deutsche Boerse AG

Last update May 23, 2024 at 11:39 am

More quotes

Static data

Product typeKnock-Out sin Stop Loss
Buy / SellPUT
Underlying MEDTRONIC PLC
IssuerLogo Issuer Société Générale Société Générale
WKN SD53WC
ISINDE000SD53WC0
Date issued 2021-05-10
Strike 127 $
Maturity Unlimited
Parity 10 : 1
Emission price 1.2
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 5.55
Lowest since issue 0.24
Spread 0.01
Spread %0.25%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
85.76 USD
Average target price
94.77 USD
Spread / Average Target
+10.51%
Consensus